A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
CONCLUSION: In patients with localized, poor prognosis HCC, pembrolizumab in addition to glass Y90 radioembolization demonstrated promising efficacy and safety consistent with prior observations (ClinicalTrials.gov Identifier: NCT03099564; IRB Approved: 16-3255 approved July 12, 2016).PMID:38325328 | DOI:10.1093/oncolo/oyad331 (Source: The Oncologist)
Source: The Oncologist - February 7, 2024 Category: Cancer & Oncology Authors: Shawn Yu Menggang Yu Barry Keane David M Mauro Paul R Helft William P Harris Hanna K Sanoff Matthew S Johnson Bert O'Neil Autumn Jackson McRee Ashwin Somasundaram Source Type: research
The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review
In conclusion, while ICI monotherapy has limited efficacy in MSS CRC, combination strategies hold promise to enhance survival outcomes. Further research is necessary to identify optimal combination approaches, predictive biomarkers for treatment response, as well as enrollment according to tumor molecular characteristics.PMID:38309719 | DOI:10.1093/oncolo/oyae013 (Source: The Oncologist)
Source: The Oncologist - February 3, 2024 Category: Cancer & Oncology Authors: Deniz Can Guven Gozde Kavgaci Enes Erul Masood Pasha Syed Tara Magge Anwaar Saeed Suayib Yalcin Ibrahim Halil Sahin Source Type: research
Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study
CONCLUSION: ChatGPT-4 and ChatGPT-3.5 are potentially powerful tools in immuno-oncology, whereas Google Bard demonstrated relatively poorer performance. However, the risk of inaccuracy or incompleteness in the responses was evident in all 3 LLMs, highlighting the importance of expert-driven verification of the outputs returned by these technologies.PMID:38309720 | DOI:10.1093/oncolo/oyae009 (Source: The Oncologist)
Source: The Oncologist - February 3, 2024 Category: Cancer & Oncology Authors: Giovanni Maria Iannantuono Dara Bracken-Clarke Fatima Karzai Hyoyoung Choo-Wosoba James L Gulley Charalampos S Floudas Source Type: research
Landscape and Saturation Analysis of Mutations Associated With Race in Cancer Genomes by Clinical Sequencing
Oncologist. 2024 Jan 31:oyad341. doi: 10.1093/oncolo/oyad341. Online ahead of print.ABSTRACTDifferences in cancer genomes between racial groups may impact tumor biology and health disparities. However, the discovery of race-associated mutations is constrained by the limited representation and sample size of different racial groups in prior genomic studies. We evaluated the influence of race on the frequency of gene mutations using the Genomics, Evidence, Neoplasia, Information, Exchange database, a large genomic dataset aggregated from clinical sequencing. Matched cohort analyses were used to identify histology-specific ra...
Source: The Oncologist - February 1, 2024 Category: Cancer & Oncology Authors: Maishara Muquith David Hsiehchen Source Type: research
Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma
CONCLUSION: IgH proportion detected in the ctDNA samples traced from tissue samples has a high clinical value in predicting the progression of DLBCL.PMID:38297976 | DOI:10.1093/oncolo/oyae008 (Source: The Oncologist)
Source: The Oncologist - February 1, 2024 Category: Cancer & Oncology Authors: Kewei Zhao Xin Zheng Xinxiu Liu Tao Liu Zhonghe Ke Fang Zhu Qiuyue Wen Beibei Xin Qiuhui Li Liling Zhang Source Type: research
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors
CONCLUSIONS: Tinengotinib was well tolerated with favorable pharmacokinetic characteristics. Preliminary findings indicated potential clinical benefit in FGFR inhibitor-refractory cholangiocarcinoma, HER2-negative breast cancer (including TNBC), and CRPC. Continued evaluation of tinengotinib is warranted in phase II trials.PMID:38297981 | DOI:10.1093/oncolo/oyad338 (Source: The Oncologist)
Source: The Oncologist - February 1, 2024 Category: Cancer & Oncology Authors: Sarina A Piha-Paul Binghe Xu Ecaterina E Dumbrava Siqing Fu Daniel D Karp Funda Meric-Bernstam David S Hong Jordi A Rodon Apostolia M Tsimberidou Kanwal Raghav Jaffer A Ajani Anthony P Conley Frank Mott Ying Fan Jean Fan Peng Peng Hui Wang Shumao Ni Caixi Source Type: research
Development of an Electronic Decision Aid Tool to Facilitate Mainstream Genetic Testing in Ovarian Cancer Patients
CONCLUSION: The DA developed in this study has the potential to facilitate informed decision-making by patients regarding cancer genetic testing. The distinctive feature of this DA is that it addresses the specific question of which multigene panel may be most suitable for the patient. Its acceptability and effectiveness will be evaluated in future studies.PMID:38297990 | DOI:10.1093/oncolo/oyad328 (Source: The Oncologist)
Source: The Oncologist - February 1, 2024 Category: Cancer & Oncology Authors: Kristen M Shannon Devanshi Patel Jessica M Jonas Erica L Blouch Stephanie R Hicks Mackenzie Wooters Meredith Seidel Carly F Grant Margaret M Emmet Daniel C Chung Karen Sepucha Source Type: research
Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US
CONCLUSION: This study documented the real-world change in CLL treatment landscape and the substantial economic burden of patients with CLL/SLL. Specifically, targeted therapies were increasingly used as 1L treatments and they were part of more than half of 1L regimens in recent years (2018-2021).PMID:38280190 | DOI:10.1093/oncolo/oyad324 (Source: The Oncologist)
Source: The Oncologist - January 27, 2024 Category: Cancer & Oncology Authors: Xiaoqin Yang Enrico Zanardo Dominique Lejeune Enrico De Nigris Eric Sarpong Mohammed Farooqui Fran çois Laliberté Source Type: research
The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214
CONCLUSION: In aRCC, patient-reported outcomes are important for HRQoL and prognostic evaluation.CLINICALTRIALS.GOV IDENTIFIER: NCT02231749; https://clinicaltrials.gov/ct2/show/NCT02231749.PMID:38280218 | DOI:10.1093/oncolo/oyae003 (Source: The Oncologist)
Source: The Oncologist - January 27, 2024 Category: Cancer & Oncology Authors: David Cella Toni K Choueiri Melissa Hamilton Steven I Blum Cristina Ivanescu Karl Karu Flavia Ejzykowicz Robert J Motzer Source Type: research
Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration
CONCLUSION: In real world, despite having similar PFS as the phase III IMbrave 150 trial, our OS at 12 months was lower (52% vs. 67%) because our study included a higher proportion of elderly patients with moderate liver dysfunction and a 40% non-White. This study provided real-world outcomes that differed from the study population in a pivotal trial.PMID:38254242 | DOI:10.1093/oncolo/oyad343 (Source: The Oncologist)
Source: The Oncologist - January 23, 2024 Category: Cancer & Oncology Authors: Munaf A Alkadimi Tamarah A Aldawoodi Kana T Lucero Maria E Fierro Lauren D Boyle Michael J Mader Kathleen R Franklin Sukeshi P Arora Zohra Nooruddin Source Type: research
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial
CONCLUSIONS: Tivozanib demonstrated a consistent safety profile and long-term survival benefit in patients with R/R advanced RCC who were alive and progression free at 12 months. These post hoc exploratory analyses of LT-PFS and conditional OS support a clinically meaningful improvement with tivozanib versus sorafenib in this advanced RCC population.PMID:38262444 | DOI:10.1093/oncolo/oyad348 (Source: The Oncologist)
Source: The Oncologist - January 23, 2024 Category: Cancer & Oncology Authors: Kathryn E Beckermann Aviva G Asnis-Alibozek Michael B Atkins Bernard Escudier Thomas E Hutson Vijay Kasturi David F McDermott Sumanta K Pal Camillo Porta Brian I Rini Elena Verzoni Source Type: research
Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study
Oncologist. 2024 Jan 18:oyad345. doi: 10.1093/oncolo/oyad345. Online ahead of print.ABSTRACTDuvelisib, a small-molecule phosphatidylinositol 3-kinase-δ,γ inhibitor, has shown efficacy for mycosis fungoides (MF) at dosage ranges of 25-100 mg twice daily (BID), but with significant toxicity. We conducted a retrospective cohort study of patients with advanced MF treated with low-dose duvelisib (15 mg every other day to BID), in an effort to minimize toxicity. A total of 7 patients were included. The overall response rate on duvelisib was 71%, with the remaining patients maintaining stable disease. Mean modified Severity Wei...
Source: The Oncologist - January 20, 2024 Category: Cancer & Oncology Authors: Christopher Bazewicz Nicolena Verardi Oleg Akilov Source Type: research
Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis
CONCLUSION: There remains an urgent need to evaluate and address CRC disparities in rural areas. Investigators should focus future work on assessing the quality of staging at diagnosis, treatment, and survivorship care in rural areas.PMID:38243853 | DOI:10.1093/oncolo/oyad347 (Source: The Oncologist)
Source: The Oncologist - January 20, 2024 Category: Cancer & Oncology Authors: Aryana Sepassi Meng Li Jason Zell Alexandre Chan Ila M Saunders Dana B Mukamel Source Type: research
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer
CONCLUSION: Our results showed that RAM plus DOC after combined chemoimmunotherapy might be an effective and relatively feasible second-line treatment for patients with advanced NSCLC in a real-world setting.PMID:38241181 | DOI:10.1093/oncolo/oyae001 (Source: The Oncologist)
Source: The Oncologist - January 19, 2024 Category: Cancer & Oncology Authors: Yuki Katayama Tadaaki Yamada Ryo Sawada Hayato Kawachi Kenji Morimoto Satoshi Watanabe Kageaki Watanabe Takayuki Takeda Yusuke Chihara Shinsuke Shiotsu Makoto Hibino Taishi Harada Naoya Nishioka Masahiro Iwasaku Shinsaku Tokuda Koichi Takayama Source Type: research
Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication
CONCLUSION: We mapped frequency and types of ribociclib-induced CAEs. An interdisciplinary management of CAEs incorporated into routine care may reduce the rate of drug discontinuation thus potentially contributing to better long-term outcomes.PMID:38242689 | DOI:10.1093/oncolo/oyae004 (Source: The Oncologist)
Source: The Oncologist - January 19, 2024 Category: Cancer & Oncology Authors: Riccardo Giovanni Borroni Michela Bartolini Mariangela Gaudio Flavia Jacobs Chiara Benvenuti Riccardo Gerosa Paola Tiberio Sofia Ada Assunta Maria Manara Alessandra Solferino Armando Santoro Rita De Sanctis Source Type: research
